SGCA
AZN icon

Steel Grove Capital Advisors’s AstraZeneca AZN Stock Holding History

Steel Grove Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-7,572
Closed -$575K – 133
2018
Q4 		$575K Sell
7,572
-315
-4% -$24.6K 0.08% 184
2018
Q3 		$624K Buy
7,887
+770
+11% +$58.2K 0.09% 178
2018
Q2 		$500K Buy
7,117
+779
+12% +$56K 0.08% 193
2018
Q1 		$443K Buy
6,338
+3,451
+120% +$239K 0.07% 224
2017
Q4 		$200K Buy
+2,887
New +$195K 0.03% 284

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Steel Grove Capital Advisors's AZN Position: Q1 2019 in Review

Steel Grove Capital Advisors sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 7,572 shares — an estimated $575K sold.

Steel Grove Capital Advisors first reported a position in AZN in Q4 2017 and held it in 5 quarters. The position peaked at $624K in Q3 2018. 561 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

  • Steel Grove Capital Advisors reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 7,572 AstraZeneca shares in Q1 2019, an estimated $575K.
  • Steel Grove Capital Advisors first reported a position in AstraZeneca in Q4 2017 and held it in 5 quarters.
  • Steel Grove Capital Advisors's AstraZeneca position peaked at $624K in Q3 2018.
  • 561 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on Steel Grove Capital Advisors's 13F filing for Q1 2019, filed 14 May 2019.